ResMed issues new research, insights into effectiveness of PAP therapy
A number of accomplished medical and scientific experts presented critical new research on sleep conditions and their effect on cardiovascular health at the American Thoracic Society International Conference. The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits. The studies were among 26 supported by ResMed. Real-world Trends of Glucagon-Like Peptide-1 Receptor Agonists and PAP Therapy Use in OSA: The use of GLP-1s did not lead to higher discontinuation rates of PAP therapy, rather this analysis found that patients who were adherent to their GLP-1 medication had higher levels of PAP therapy use than those who were non-adherent to their GLP-1 medication. PAP Therapy Continues to Lower Risks Associated with Sleep Disorders: This meta-study, presented by Dr. Atul Malhotra, found mortality was 37% lower on average in patients with PAP-treated OSA vs untreated OSA. Examining the Prevalence of Obstructive Sleep Apnea in the United States: A study presented by ResMed's research scientist Elroy Boers projected an increase in OSA cases in the United States using patient data calibrated across subgroups of age, sex and body-mass index. Adaptive Servo-Ventilation Patients with Treatment Emergent or Persistent Central Sleep Apnea and Central Sleep Apnea induced by Opioid Use: Two studies evaluated the effects of Adaptive Servo-Ventilation therapy in two populations. One study demonstrated ASV therapy showed a reduced symptom burden and an improvement in quality of life for patients with TE-CSA, with or without comorbid cardiovascular disease, a comorbidity present in a majority of patients with TE-CSA. The second study showed a -1 median reduction in Epworth Sleepiness Scale values and a median increase of .96 on the Functional Outcomes of Sleep Questionnaire, demonstrating a lower symptom burden and improved quality of life. Reducing Risk of Death in COPD Patients with Non-Invasive Ventilation at Home: Another study, also presented by Dr. Jean-Louis Pepin, looked at nearly 50,000 adults with COPD who were treated via domiciliary NIV. The study showed long-term home use of NIV was strongly associated with a reduced risk of death.
